BR0010316A - Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente - Google Patents

Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente

Info

Publication number
BR0010316A
BR0010316A BR0010316-0A BR0010316A BR0010316A BR 0010316 A BR0010316 A BR 0010316A BR 0010316 A BR0010316 A BR 0010316A BR 0010316 A BR0010316 A BR 0010316A
Authority
BR
Brazil
Prior art keywords
dosage regimens
epo
pharmacodynamic
pharmacokinetic
patient
Prior art date
Application number
BR0010316-0A
Other languages
English (en)
Inventor
Wing Cheung
David Gibson
Christine Cote
Els Vercammen
Original Assignee
Ortho Mcnell Pharmaceutical In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22458537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0010316(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcnell Pharmaceutical In filed Critical Ortho Mcnell Pharmaceutical In
Publication of BR0010316A publication Critical patent/BR0010316A/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Computing Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Primary Health Care (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)

Abstract

"MéTODO E SISTEMA PARA OBTENçãO DE REGIMES DE DOSAGEM OTIMIZADOS DE EPO PARA UMA RESPOSTA FARMACODINâMICA/FARMACOCINéTICA DESEJADA EM UM PACIENTE". A presente invenção está relacionada a sistemas e métodos para obtenção de regimes de dosagem otimizados de EPO para uma resposta farmacodinâmica/farmacocinética desejada. O sistema inclui a escolha de um ou mais regimes de dosagem de EPO, então o uso de um modelo farmacodinâmico/farmacocinético para determinar o perfil farmacodinâmico/farmacocinético de um ou mais regimes de dosagem de EPO, e finalmente selecionar um dos regimes de dosagem de EPO para que a administração atinja a resposta farmacodinâmica/farmacocinética desejada baseada no perfil de EPO.
BR0010316-0A 1999-05-11 2000-05-10 Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente BR0010316A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13341899P 1999-05-11 1999-05-11
PCT/US2000/012629 WO2000067776A1 (en) 1999-05-11 2000-05-10 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration

Publications (1)

Publication Number Publication Date
BR0010316A true BR0010316A (pt) 2004-04-27

Family

ID=22458537

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010316-0A BR0010316A (pt) 1999-05-11 2000-05-10 Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente

Country Status (16)

Country Link
US (5) US6747002B2 (pt)
EP (1) EP1176975A4 (pt)
JP (2) JP2003523940A (pt)
KR (1) KR20020008186A (pt)
CN (2) CN1367701A (pt)
AU (2) AU4838600A (pt)
BR (1) BR0010316A (pt)
CA (1) CA2372782A1 (pt)
HU (1) HUP0300333A3 (pt)
IL (1) IL146206A0 (pt)
MX (1) MXPA01011429A (pt)
NO (1) NO20015323L (pt)
PL (1) PL360581A1 (pt)
RU (1) RU2248215C2 (pt)
WO (2) WO2000067776A1 (pt)
ZA (1) ZA200109527B (pt)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
EP1316048A2 (en) 2000-05-18 2003-06-04 ALARIS Medical Systems, Inc. Distributed remote asset and medication management drug delivery system
US10353856B2 (en) 2011-03-17 2019-07-16 Carefusion 303, Inc. Scalable communication system
US7860583B2 (en) 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
US11087873B2 (en) 2000-05-18 2021-08-10 Carefusion 303, Inc. Context-aware healthcare notification system
US10062457B2 (en) 2012-07-26 2018-08-28 Carefusion 303, Inc. Predictive notifications for adverse patient events
US9427520B2 (en) 2005-02-11 2016-08-30 Carefusion 303, Inc. Management of pending medication orders
US9741001B2 (en) 2000-05-18 2017-08-22 Carefusion 303, Inc. Predictive medication safety
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1930023A3 (en) * 2001-04-09 2008-08-06 East Carolina University Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
AU2002340463A1 (en) * 2001-11-16 2003-06-10 Children's Medical Center Corporation Augmentation of organ function
BR0214557A (pt) 2001-11-28 2006-06-06 Ortho Mcneil Pharm Inc regime de dosagem de eritropoietina para o tratamento de anemia
US20030157073A1 (en) 2001-11-29 2003-08-21 Peritt David L. Methods for pretreating a subject with apoptotic cells
ES2414706T3 (es) * 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
JP2004238392A (ja) * 2003-01-14 2004-08-26 Nipro Corp 安定化された蛋白質性製剤
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
DE102004010516A1 (de) * 2004-03-04 2005-09-22 Bayer Technology Services Gmbh Verbessertes Verfahren zur zeitlichen Dosierung von Arzneistoffen
US20050282751A1 (en) * 2004-03-19 2005-12-22 Ajinomoto Co., Inc. Therapeutic agent for renal anemia
MXPA06011084A (es) * 2004-03-26 2007-03-21 Johnson & Johnson Regimen de dosificacion en comunicacion para eritropoyetina.
WO2006021894A2 (en) 2004-08-26 2006-03-02 Engeneic Gene Therapy Pty Limited Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
HUE038724T2 (hu) 2004-11-24 2018-11-28 Bayer Healthcare Llc Eszközök és összeállítások fluidumbejuttatáshoz
JP2008544214A (ja) 2005-05-09 2008-12-04 セラノス， インコーポレイテッド ポイントオブケア流体システムおよびその使用
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CN102743382B (zh) 2005-09-19 2016-12-07 诺伊罗纳森特公司 刺激神经形成和抑制神经元变性的方法和组合物
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
CN101046831B (zh) * 2006-03-31 2010-09-08 上海中医药大学 中药多组分药动-药效结合数学模型的构建和计算方法
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US8007999B2 (en) 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
AU2007278899B2 (en) 2006-06-23 2012-09-06 Engenelc Molecular Delivery Pty. Ltd. Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
US8012744B2 (en) 2006-10-13 2011-09-06 Theranos, Inc. Reducing optical interference in a fluidic device
US20080113391A1 (en) 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
EP2097835B1 (en) 2006-12-29 2018-05-30 Bayer Healthcare LLC Patient-based parameter generation systems for medical injection procedures
CN101715489B (zh) 2007-03-30 2016-05-25 因詹尼克分子递送控股有限公司 用于体内递送至哺乳动物细胞的、包含无质粒的功能性核酸的、源自细菌的完整小细胞
EP1992355A1 (en) * 2007-05-16 2008-11-19 Eberhardt Spanuth Pharmaceutical combination medication comprising NSAIDs or cytoxic drugs
CN103865871A (zh) * 2007-06-08 2014-06-18 韦克福里斯特大学健康科学院 治疗肾功能衰竭的选择性细胞疗法
US9580688B2 (en) * 2007-06-08 2017-02-28 Wake Forest University Health Sciences Kidney structures and methods of forming the same
US10590391B2 (en) * 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
CA2693062C (en) 2007-06-21 2016-08-09 Neuronascent, Inc. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
CA3138078C (en) 2007-10-02 2024-02-13 Labrador Diagnostics Llc Modular point-of-care devices and uses thereof
CN101965514A (zh) * 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
NZ593207A (en) * 2008-11-12 2012-10-26 Tengion Inc Isolated renal cells and uses thereof
NZ599873A (en) 2009-10-19 2014-09-26 Theranos Inc Integrated health data capture and analysis system
WO2011072216A2 (en) 2009-12-11 2011-06-16 The Johns Hopkins University Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
EP2521983A1 (en) 2010-01-04 2012-11-14 Mayo Foundation for Medical Education and Research Erythropoietic stimulating agent (esa) dosage determination
EP2549992B1 (en) 2010-03-23 2019-08-14 The Johns Hopkins University Methods of treatment using stem cell mobilizers
US20130052136A1 (en) * 2010-03-23 2013-02-28 Fresenius Medical Care Deutschland Gmbh Methods and apparatuses for predicting the effects of erythropoiesis stimulating agents, and for determining a dose to be administered
US9057731B2 (en) 2010-06-23 2015-06-16 University Of Louisville Research Foundation, Inc. Methods and kits for predicting a response to an erythropoietic agent
CN103221071B (zh) * 2010-06-24 2016-09-21 拜耳医药保健有限公司 药物传输的建模和注射方案的参数产生
KR102302069B1 (ko) 2010-11-10 2021-09-14 인리젠 장기 확대를 위한 주사가능 제제
CN106290160A (zh) 2011-01-21 2017-01-04 提拉诺斯公司 样品使用最大化的系统和方法
JP6184943B2 (ja) * 2011-05-30 2017-08-23 オートテリック エルエルシー ポイント・オブ・ケア薬物動態プロフィールによる治療薬モニタリングおよび用量投与のための方法および組成物
US9852267B2 (en) 2011-09-30 2017-12-26 University Of Louisville Research Foundation, Inc. System and method for personalized dosing of pharmacologic agents
CN102663218B (zh) * 2011-10-28 2017-12-19 天津大学 氟喹诺酮类抗菌药基于理化性质的药时曲线预测模型
DK3489667T3 (da) 2012-05-14 2021-08-02 Bayer Healthcare Llc Systemer og fremgangsmåder til bestemmelse af protokoller for farmaceutisk væskeinjektion baseret på røntgenrørsspænding
EP2895973B1 (en) 2012-09-14 2024-07-24 The University of Massachusetts Methods and devices for determining optimal agent dosages
US20140114676A1 (en) * 2012-10-23 2014-04-24 Theranos, Inc. Drug Monitoring and Regulation Systems and Methods
US11182728B2 (en) 2013-01-30 2021-11-23 Carefusion 303, Inc. Medication workflow management
US10430554B2 (en) 2013-05-23 2019-10-01 Carefusion 303, Inc. Medication preparation queue
WO2014190200A1 (en) 2013-05-22 2014-11-27 Carefusion 303, Inc. Medication workflow management
CN114267429A (zh) 2013-03-13 2022-04-01 康尔福盛303公司 预测性用药安全
BR112015019758B1 (pt) 2013-03-13 2022-07-05 Carefusion 303, Inc Sistema e método para uso com dispositivo médico para reduzir erros de medicação e meio de armazenamento legível à maquina
US9849241B2 (en) * 2013-04-24 2017-12-26 Fresenius Kabi Deutschland Gmbh Method of operating a control device for controlling an infusion device
EP4091609A1 (en) 2013-04-29 2022-11-23 Medregen, LLC Wound healing via autologous stem cell mobilization
JP6190632B2 (ja) * 2013-06-13 2017-08-30 有限会社ネクスティア 赤血球造血刺激因子製剤の投与量決定装置
GEP20186882B (en) * 2013-06-20 2018-07-25 Baxalta Inc Providing a pharmacokinetic drug dosing regime
CN103336902B (zh) * 2013-06-27 2016-01-13 西安交通大学 一种基于模拟分布平衡血药浓度的药物绝对生物利用度检测方法
CN105658233B (zh) 2013-10-04 2020-09-04 安吉尼科分子传输公司 使用携带药物的、双特异性配体靶向的微细胞和干扰素-γ的联合肿瘤治疗
ES2968371T3 (es) 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
CA2963218C (en) 2014-10-03 2023-10-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US11253511B2 (en) 2016-01-04 2022-02-22 The Johns Hopkins University Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)
JP6942721B2 (ja) 2016-04-15 2021-09-29 バクスアルタ インコーポレイティッド 薬物動態学的薬物投与計画を提供する方法及び装置
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
IL265855B1 (en) 2016-10-06 2024-08-01 Engeneic Molecular Delivery Pty Ltd Bacterial cell species for transporting nucleic acid adjuvants and methods of using them
CN106682396A (zh) * 2016-12-09 2017-05-17 贵州医科大学 中药组方中四种代表成分的pk‑pd结合模型的建立方法
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
JP6864834B2 (ja) * 2017-06-14 2021-04-28 ニプロ株式会社 投与量決定プログラムおよび投与量決定装置
WO2020021437A1 (en) 2018-07-23 2020-01-30 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same
CN108776747B (zh) * 2018-08-15 2022-02-01 余鹏 齐多夫定的药效估算方法
WO2020086934A2 (en) * 2018-10-26 2020-04-30 Abbott Diabetes Care Inc. Methods, devices, and systems for physiological parameter analysis
CA3127613A1 (en) 2019-01-23 2020-07-30 The Johns Hopkins University Non-immunosuppressive fk506 analogs and use thereof
CN110487945B (zh) * 2019-08-20 2021-06-04 中山大学 一种针对药物多峰现象的犬药代动力学模型的创建方法
WO2023086292A2 (en) 2021-11-10 2023-05-19 University Of Rochester Gata4-targeted therapeutics for treatment of cardiac hypertrophy
CA3237770A1 (en) 2021-11-10 2023-05-19 University Of Rochester Antisense oligonucleotides for modifying protein expression
WO2024050261A1 (en) 2022-08-29 2024-03-07 University Of Rochester Antisense oligonucleotide-based anti-fibrotic therapeutics

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732889A (en) 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US4748600A (en) 1986-08-22 1988-05-31 Aprex Corporation Interactive drug dispenser
JP2858752B2 (ja) 1987-04-10 1999-02-17 オーソ・フアーマシユーチカル・コーポレーシヨン 正常な哺乳動物のヘマトクリツト値の増大方法
JP2632014B2 (ja) 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US5416907A (en) * 1990-06-15 1995-05-16 Digital Equipment Corporation Method and apparatus for transferring data processing data transfer sizes
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
ES2208798T3 (es) * 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
US6067524A (en) * 1999-01-07 2000-05-23 Catalina Marketing International, Inc. Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data

Also Published As

Publication number Publication date
WO2000067769A8 (en) 2001-02-08
US20040157778A1 (en) 2004-08-12
CN1572320A (zh) 2005-02-02
RU2248215C2 (ru) 2005-03-20
HUP0300333A2 (hu) 2003-06-28
MXPA01011429A (es) 2003-09-10
US20060100150A1 (en) 2006-05-11
US20060128624A1 (en) 2006-06-15
HUP0300333A3 (en) 2009-01-28
CA2372782A1 (en) 2000-11-16
CN1367701A (zh) 2002-09-04
AU4838600A (en) 2000-11-21
JP2003523940A (ja) 2003-08-12
NO20015323L (no) 2002-01-11
PL360581A1 (en) 2004-09-06
WO2000067769A1 (en) 2000-11-16
ZA200109527B (en) 2003-10-20
US20030198691A1 (en) 2003-10-23
AU4709400A (en) 2000-11-21
EP1176975A1 (en) 2002-02-06
NO20015323D0 (no) 2001-10-31
EP1176975A4 (en) 2004-12-01
US20040176297A1 (en) 2004-09-09
WO2000067776A1 (en) 2000-11-16
US6747002B2 (en) 2004-06-08
WO2000067776A9 (en) 2003-09-04
IL146206A0 (en) 2002-07-25
JP2005247858A (ja) 2005-09-15
KR20020008186A (ko) 2002-01-29

Similar Documents

Publication Publication Date Title
BR0010316A (pt) Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente
AU9028498A (en) System, method and cassette for mixing and delivering intravenous drugs
NO20013419D0 (no) Substituerte 2-aryl-3-(heteroaryl)-imidazo[1,2a]pyrimidiner, med dertil hörende farmasöytiske preparater samt metoder.
WO2003100560A3 (en) Learning system
NO20013052L (no) Styremetode for anvendelse med et boresystem
IT1303246B1 (it) Procedimento per l'installazione e/o la verifica del software per unsistema di computer prodotto su ordinazione, e sistema di computer per
BR0012595A (pt) Ligação de fonte de dados de célula em folha de desenvolvimento
ITRM920590A1 (it) Sistema per la realizzazione distrutture in fibra di carbonio, e procedimento per detto, particolarmente idoneo per applicazioni aeronautiche.
DE69925374D1 (de) Spinales osteosynthesesystem mit verbesserter stabilität
DK141492D0 (da) Stabil lavviskos bimodal olie-i-vand-emulsion samt fremgangsmaade til fremstilling deraf
DE69837461D1 (de) Rechner Systemverwaltung über das Internet
IT1303245B1 (it) Apparecchio per facilitare l'installazione e la verifica del softwareper un sistema di computer prodotto su ordinazione.
DK1098874T3 (da) Benzocycloheptener, fremgangsmåder til deres fremstilling, farmaceutiske præparater, som indeholder disse, samt deres anvendelse til fremstilling af lægemidler
AU6364400A (en) Method and system for computer aided embroidery
NO932636L (no) Benzimidazoler, medikamenter inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling
DK188286A (da) Phenylalkyl-2,3-dihydrobenzofuraner og analoge heraf samt praeparater indeholdende disse forbindelser
BR9400807A (pt) Método para medir diretamente a concentração de um ou mais componentes de composições de tratamento de água, métodos para determinar os ciclos de concentração, os requisitos de dosagem de polímero e a perda de polímero em um sistema gerador de vapor d'agua
ITTO930220A0 (it) Procedimento per il controllo delle condizioni termiche in un ambientee relativo sistema.
EP1271358A3 (en) Copying a portion of a database structure associated with a query
DE69016543D1 (de) Fussbodenpaneel und Vorrichtung zu dessen Herstellung.
AU6916698A (en) Method for the functional detection of disorders in the protein c system
NO993125L (no) Steroider substituert i posisjon 11, fremgangsmåte for fremstilling av disse, deres anvendelse som medisiner samt farmasöytiske preparater inneholdende disse
ES2108246T3 (es) Procedimiento y sistema de inscripcion de una informacion sobre un soporte que permite certificar ulteriormente la originalidad de esta informacion.
大田堯 et al. The Education of Man-The Foundation of Human Development-A Lecture
小股泰子 Application of glass ODS for the HPLC analysis of estrone 17-β-estradiol and estriol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.